Drugs / Human chorionic gonadotrophin (hCG)
Human chorionic gonadotrophin (hCG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT02640976 Comparator | Jun 2013 → Jun 2015 | female infertility | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT07481370 Comparator | Apr 2026 → Jun 2027 expected | azoospermia, oligospermia | University of Nebraska | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human chorionic gonadotrophin (hCG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02640976 ↗ |
| Known as | hCG | “Human chorionic gonadotropin (hCG) administered by subcutaneous injection at a dose of 2,000 units three times weekly for 3 months as part of a randomized treatment arm...” NCT07481370 ↗ |
| Known as | Human chorionic gonadotropin | “Human chorionic gonadotropin (hCG) administered by subcutaneous injection at a dose of 2,000 units three times weekly for 3 months as part of a randomized treatment arm...” NCT07481370 ↗ |
| Route | Intramuscular | “ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®” NCT02640976 ↗ |